And as previously mentioned in this call, we are raising our Capilator full year 2023 net product sales guidance range to $460,000,000 to $470,000,000 Selling, general and administrative expenses were 105 point $2,000,000 for the Q3 of 2023 compared to $88,400,000 for the same period in 2022. Research and development expenses for the Q3 of 2023 were $41,600,000 compared to $33,300,000 for the same period in 20 For 2023, we are lowering our estimated full year SG and A expense range to $405,000,000 to $420,000,000 and we're lowering our estimated full year R and D expense range to $185,000,000 to $200,000,000 Our financial position remains strong. Cash, cash equivalents, investment securities, Restricted cash totaled $494,800,000 at September 30, 2023. This concludes our prepared remarks. Operator, please open the line for questions.